Hemophilia A Pipeline Review H1 2017
ReportsWeb.com has announced the addition of the “Hemophilia A Pipeline Review H1 2017” this report provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.
(EMAILWIRE.COM, June 01, 2017 ) Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII) , which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 6, 5, 1, 20, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/hemophilia-a-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders) .
- The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001799294/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Alnylam Pharmaceuticals Inc
Amarna Therapeutics BV
Apitope International NV
Bayer AG
BioMarin Pharmaceutical Inc
Bioverativ Inc
Catalyst Biosciences Inc
Chugai Pharmaceutical Co Ltd
CSL Ltd
DBV Technologies SA
Dimension Therapeutics Inc
Emergent BioSolutions Inc
EpiVax Inc
Expression Therapeutics LLC
Green Cross Corp
Idogen AB
Immusoft Corp
Lentigen Technology Inc
mAbxience SA
Novo Nordisk A/S
OPKO Biologics Ltd
Pangen Biotech Inc.
Pfizer Inc
Pharming Group NV
Promethera Biosciences SA
rEVO Biologics Inc
Sangamo Therapeutics Inc
Shire Plc
SK Chemicals Co Ltd
Spark Therapeutics Inc
UniQure NV
XL-protein GmbH
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001799294/discount
List of Tables
Number of Products under Development for Hemophilia A, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Hemophilia A - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
Hemophilia A - Pipeline by Amarna Therapeutics BV, H1 2017
Hemophilia A - Pipeline by Apitope International NV, H1 2017
Hemophilia A - Pipeline by Bayer AG, H1 2017
Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H1 2017
Hemophilia A - Pipeline by Bioverativ Inc, H1 2017
Hemophilia A - Pipeline by Catalyst Biosciences Inc, H1 2017
Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Hemophilia A - Pipeline by CSL Ltd, H1 2017
Hemophilia A - Pipeline by DBV Technologies SA, H1 2017
Hemophilia A - Pipeline by Dimension Therapeutics Inc, H1 2017
Hemophilia A - Pipeline by Emergent BioSolutions Inc, H1 2017
Hemophilia A - Pipeline by EpiVax Inc, H1 2017
Hemophilia A - Pipeline by Expression Therapeutics LLC, H1 2017
Hemophilia A - Pipeline by Green Cross Corp, H1 2017
Hemophilia A - Pipeline by Idogen AB, H1 2017
Hemophilia A - Pipeline by Immusoft Corp, H1 2017
Hemophilia A - Pipeline by Lentigen Technology Inc, H1 2017
Hemophilia A - Pipeline by mAbxience SA, H1 2017
Hemophilia A - Pipeline by Novo Nordisk A/S, H1 2017
Hemophilia A - Pipeline by OPKO Biologics Ltd, H1 2017
Hemophilia A - Pipeline by Pangen Biotech Inc., H1 2017
Hemophilia A - Pipeline by Pfizer Inc, H1 2017
Hemophilia A - Pipeline by Pharming Group NV, H1 2017
Hemophilia A - Pipeline by Promethera Biosciences SA, H1 2017
Hemophilia A - Pipeline by rEVO Biologics Inc, H1 2017
Hemophilia A - Pipeline by Sangamo Therapeutics Inc, H1 2017
Hemophilia A - Pipeline by Shire Plc, H1 2017
Hemophilia A - Pipeline by SK Chemicals Co Ltd, H1 2017
Hemophilia A - Pipeline by Spark Therapeutics Inc, H1 2017
Hemophilia A - Pipeline by UniQure NV, H1 2017
Hemophilia A - Pipeline by XL-protein GmbH, H1 2017
Hemophilia A - Dormant Projects, H1 2017
Hemophilia A - Dormant Projects, H1 2017 (Contd..1) , H1 2017
Hemophilia A - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001799294/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 6, 5, 1, 20, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/hemophilia-a-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders) .
- The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001799294/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Alnylam Pharmaceuticals Inc
Amarna Therapeutics BV
Apitope International NV
Bayer AG
BioMarin Pharmaceutical Inc
Bioverativ Inc
Catalyst Biosciences Inc
Chugai Pharmaceutical Co Ltd
CSL Ltd
DBV Technologies SA
Dimension Therapeutics Inc
Emergent BioSolutions Inc
EpiVax Inc
Expression Therapeutics LLC
Green Cross Corp
Idogen AB
Immusoft Corp
Lentigen Technology Inc
mAbxience SA
Novo Nordisk A/S
OPKO Biologics Ltd
Pangen Biotech Inc.
Pfizer Inc
Pharming Group NV
Promethera Biosciences SA
rEVO Biologics Inc
Sangamo Therapeutics Inc
Shire Plc
SK Chemicals Co Ltd
Spark Therapeutics Inc
UniQure NV
XL-protein GmbH
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001799294/discount
List of Tables
Number of Products under Development for Hemophilia A, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Hemophilia A - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
Hemophilia A - Pipeline by Amarna Therapeutics BV, H1 2017
Hemophilia A - Pipeline by Apitope International NV, H1 2017
Hemophilia A - Pipeline by Bayer AG, H1 2017
Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H1 2017
Hemophilia A - Pipeline by Bioverativ Inc, H1 2017
Hemophilia A - Pipeline by Catalyst Biosciences Inc, H1 2017
Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Hemophilia A - Pipeline by CSL Ltd, H1 2017
Hemophilia A - Pipeline by DBV Technologies SA, H1 2017
Hemophilia A - Pipeline by Dimension Therapeutics Inc, H1 2017
Hemophilia A - Pipeline by Emergent BioSolutions Inc, H1 2017
Hemophilia A - Pipeline by EpiVax Inc, H1 2017
Hemophilia A - Pipeline by Expression Therapeutics LLC, H1 2017
Hemophilia A - Pipeline by Green Cross Corp, H1 2017
Hemophilia A - Pipeline by Idogen AB, H1 2017
Hemophilia A - Pipeline by Immusoft Corp, H1 2017
Hemophilia A - Pipeline by Lentigen Technology Inc, H1 2017
Hemophilia A - Pipeline by mAbxience SA, H1 2017
Hemophilia A - Pipeline by Novo Nordisk A/S, H1 2017
Hemophilia A - Pipeline by OPKO Biologics Ltd, H1 2017
Hemophilia A - Pipeline by Pangen Biotech Inc., H1 2017
Hemophilia A - Pipeline by Pfizer Inc, H1 2017
Hemophilia A - Pipeline by Pharming Group NV, H1 2017
Hemophilia A - Pipeline by Promethera Biosciences SA, H1 2017
Hemophilia A - Pipeline by rEVO Biologics Inc, H1 2017
Hemophilia A - Pipeline by Sangamo Therapeutics Inc, H1 2017
Hemophilia A - Pipeline by Shire Plc, H1 2017
Hemophilia A - Pipeline by SK Chemicals Co Ltd, H1 2017
Hemophilia A - Pipeline by Spark Therapeutics Inc, H1 2017
Hemophilia A - Pipeline by UniQure NV, H1 2017
Hemophilia A - Pipeline by XL-protein GmbH, H1 2017
Hemophilia A - Dormant Projects, H1 2017
Hemophilia A - Dormant Projects, H1 2017 (Contd..1) , H1 2017
Hemophilia A - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001799294/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results